1. Medtech Insight
  2. >>Device Area
  3. >>Oncology

Oncimmune Kicks Off 2018 With China Pact For Lung Cancer Test

 
• By Tina Tan

Oncimmune's commercialization of its early cancer diagnostic technology continues to gather pace as the firm enlists yet another distribution partner in Asia. The exclusive deal is for China, where the market opportunity for the company's EarlyCDT-Lung test is sizeable. The agreement also includes an equity investment by the Chinese partner in Oncimmune.

MT1801_Lung Cancer_47781766_1200

Oncimmune Ltd. has scored its eighth Asian partner – this time, for the enormous Chinese market – to commercialize its EarlyCDT autoantibody-based cancer test platform. The deal will bring in royalty payments for Oncimmune from sales of the tests in China and a new shareholder as its new partner has agreed to make an equity investment in Nottingham, UK-based Oncimmune.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Oncology

OneCell Diagnostics – Now 1Cell.Ai - Launches Multi-Modal Cancer Diagnostic Panel OncoIncytes

 
• By Natasha Barrow

OneCell Diagnostics, the Mumbai-based startup backed with $16m in series A funding, is rebranding to 1Cell.Ai to represent the firm's focus on combining deep science with AI-powered capabilities.

MedStar Teams Up With Reimagine Care To Extend Cancer Care Into Patients’ Home

 
• By Marion Webb

Reimagine Care teamed up with MedStar Health to support cancer patients at home via an AI assistant and clinical support. Reimagine Care’s data suggests its platform can save cancer centers up to $1m annually per full-time oncologist panel and reduce ED visits by 30%.

Exact Sciences Launches Cologuard Plus

 
• By Natasha Barrow

The Cologuard Plus test has a sensitivity of 95% and a specificity of 94% for the detection of colorectal cancer; “unmatched accuracy,” according to Exact Sciences.

Wired Health: ‘Early Diagnosis Often Benefits Science But Not The Patient’

 
• By Natasha Barrow

Early diagnosis can be “detrimental” to patients, Suzanne O'Sullivan, neurologist and author of “The Age of Diagnosis,” argued at the Wired Health conference on 18 March. "You save one life from screening 2,000 women for breast cancer, but you also treat 10 women unnecessarily," she said.

More from Device Area

Looking Back Towards The Future

 
• By Brian Bossetta

As it celebrates 75 years shaping the medtech industry, Medtronic invited Medtech Insight to its Minneapolis headquarters to get a closer look at the company’s past, what it’s working on now, and what’s on the horizon.

J&J Medtech’s FDA-Cleared DUALTO System Prepares For Future Use With OTTAVA Robotic Platform

 
• By Shubham Singh

DUALTO’s double-module option provides enhanced flexibility while cutting down on equipment clutter. Compared to traditional setups, the system reduces OR footprint by 46%, helping staff reclaim space and optimize surgical workflows.

Edwards Mitral Valve Replacement System SAPIEN M3 Receives CE Mark

 
• By Natasha Barrow

“We believe [the SAPIEN M3] launch alongside PASCAL and EVOQUE will help support the company’s target of $2bn in transcatheter mitral and tricuspid therapies sales by 2030,” noted analysts from Leerink Partners.